These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 17575071

  • 1. OX40 costimulation turns off Foxp3+ Tregs.
    Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N, Li XC.
    Blood; 2007 Oct 01; 110(7):2501-10. PubMed ID: 17575071
    [Abstract] [Full Text] [Related]

  • 2. OX40/OX40L costimulation affects induction of Foxp3+ regulatory T cells in part by expanding memory T cells in vivo.
    Xiao X, Kroemer A, Gao W, Ishii N, Demirci G, Li XC.
    J Immunol; 2008 Sep 01; 181(5):3193-201. PubMed ID: 18713990
    [Abstract] [Full Text] [Related]

  • 3. OX40 controls functionally different T cell subsets and their resistance to depletion therapy.
    Kroemer A, Xiao X, Vu MD, Gao W, Minamimura K, Chen M, Maki T, Li XC.
    J Immunol; 2007 Oct 15; 179(8):5584-91. PubMed ID: 17911646
    [Abstract] [Full Text] [Related]

  • 4. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.
    Xiao X, Gong W, Demirci G, Liu W, Spoerl S, Chu X, Bishop DK, Turka LA, Li XC.
    J Immunol; 2012 Jan 15; 188(2):892-901. PubMed ID: 22147766
    [Abstract] [Full Text] [Related]

  • 5. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
    Kitamura N, Murata S, Ueki T, Mekata E, Reilly RT, Jaffee EM, Tani T.
    Int J Cancer; 2009 Aug 01; 125(3):630-8. PubMed ID: 19455675
    [Abstract] [Full Text] [Related]

  • 6. CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion.
    St Rose MC, Taylor RA, Bandyopadhyay S, Qui HZ, Hagymasi AT, Vella AT, Adler AJ.
    Immunol Cell Biol; 2013 Feb 01; 91(2):173-83. PubMed ID: 23295363
    [Abstract] [Full Text] [Related]

  • 7. OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.
    Lai C, August S, Albibas A, Behar R, Cho SY, Polak ME, Theaker J, MacLeod AS, French RR, Glennie MJ, Al-Shamkhani A, Healy E.
    Clin Cancer Res; 2016 Aug 15; 22(16):4236-48. PubMed ID: 27034329
    [Abstract] [Full Text] [Related]

  • 8. OX40 is required for regulatory T cell-mediated control of colitis.
    Griseri T, Asquith M, Thompson C, Powrie F.
    J Exp Med; 2010 Apr 12; 207(4):699-709. PubMed ID: 20368580
    [Abstract] [Full Text] [Related]

  • 9. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.
    Bresson D, Fousteri G, Manenkova Y, Croft M, von Herrath M.
    J Autoimmun; 2011 Dec 12; 37(4):342-51. PubMed ID: 22063316
    [Abstract] [Full Text] [Related]

  • 10. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation.
    Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, Fan J, Epstein AL, Maker AV, Prabhakar BS.
    Cell Mol Immunol; 2019 Feb 12; 16(2):138-153. PubMed ID: 29578532
    [Abstract] [Full Text] [Related]

  • 11. OX40L/OX40 axis impairs follicular and natural Treg function in human SLE.
    Jacquemin C, Augusto JF, Scherlinger M, Gensous N, Forcade E, Douchet I, Levionnois E, Richez C, Lazaro E, Duffau P, Truchetet ME, Seneschal J, Couzi L, Pellegrin JL, Viallard JF, Schaeverbeke T, Pascual V, Contin-Bordes C, Blanco P.
    JCI Insight; 2018 Dec 20; 3(24):. PubMed ID: 30568041
    [Abstract] [Full Text] [Related]

  • 12. A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen.
    Kinnear G, Wood KJ, Fallah-Arani F, Jones ND.
    J Immunol; 2013 Aug 01; 191(3):1465-75. PubMed ID: 23817421
    [Abstract] [Full Text] [Related]

  • 13. OX40 Costimulation Inhibits Foxp3 Expression and Treg Induction via BATF3-Dependent and Independent Mechanisms.
    Zhang X, Xiao X, Lan P, Li J, Dou Y, Chen W, Ishii N, Chen S, Xia B, Chen K, Taparowsky E, Li XC.
    Cell Rep; 2018 Jul 17; 24(3):607-618. PubMed ID: 30021159
    [Abstract] [Full Text] [Related]

  • 14. OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3+ Tregs.
    Chen M, Xiao X, Demirci G, Li XC.
    Transplantation; 2008 Jun 15; 85(11):1659-62. PubMed ID: 18551075
    [Abstract] [Full Text] [Related]

  • 15. The role of OX40-mediated co-stimulation in T-cell activation and survival.
    Redmond WL, Ruby CE, Weinberg AD.
    Crit Rev Immunol; 2009 Jun 15; 29(3):187-201. PubMed ID: 19538134
    [Abstract] [Full Text] [Related]

  • 16. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40.
    Hamano R, Huang J, Yoshimura T, Oppenheim JJ, Chen X.
    Eur J Immunol; 2011 Jul 15; 41(7):2010-20. PubMed ID: 21491419
    [Abstract] [Full Text] [Related]

  • 17. Anti-CD4 treatment inhibits autoimmunity in scurfy mice through the attenuation of co-stimulatory signals.
    Mayer CT, Tian L, Hesse C, Kühl AA, Swallow M, Kruse F, Thiele M, Gershwin ME, Liston A, Sparwasser T.
    J Autoimmun; 2014 May 15; 50():23-32. PubMed ID: 24075450
    [Abstract] [Full Text] [Related]

  • 18. IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.
    Imianowski CJ, Kuo P, Whiteside SK, von Linde T, Wesolowski AJ, Conti AG, Evans AC, Baird T, Morris BI, Fletcher NE, Yang J, Poon E, Lakins MA, Yamamoto M, Brewis N, Morrow M, Roychoudhuri R.
    Cancer Res Commun; 2024 Aug 01; 4(8):2045-2057. PubMed ID: 38995700
    [Abstract] [Full Text] [Related]

  • 19. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.
    Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, Kwak LW, Liu YJ.
    J Immunol; 2013 Oct 01; 191(7):3641-50. PubMed ID: 24014877
    [Abstract] [Full Text] [Related]

  • 20. Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.
    Panda AK, Kim YH, Shevach EM.
    J Immunol; 2022 Feb 15; 208(4):851-860. PubMed ID: 35039334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.